Copyright Reports & Markets. All rights reserved.

Global Hepatic Encephalopathy (HE) Therapeutics Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Hepatic Encephalopathy (HE) Therapeutics Market Overview

      • 1.1 Product Overview and Scope of Hepatic Encephalopathy (HE) Therapeutics
      • 1.2 Hepatic Encephalopathy (HE) Therapeutics Segment by Type
        • 1.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 Lactulose
        • 1.2.3 Rifaximin
        • 1.2.4 Neomycin
        • 1.2.5 Probiotics
        • 1.2.6 Thiamine
      • 1.3 Hepatic Encephalopathy (HE) Therapeutics Segment by Application
        • 1.3.1 Hepatic Encephalopathy (HE) Therapeutics Consumption Comparison by Application (2014-2025)
        • 1.3.2 Acute Liver Failure
        • 1.3.3 Portal Systemic Bypass Without Liver Disease
        • 1.3.4 Liver Cirrhosis
      • 1.4 Global Hepatic Encephalopathy (HE) Therapeutics Market by Region
        • 1.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Region
        • 1.4.2 North America Status and Prospect (2014-2025)
        • 1.4.3 Europe Status and Prospect (2014-2025)
        • 1.4.4 China Status and Prospect (2014-2025)
        • 1.4.5 Japan Status and Prospect (2014-2025)
      • 1.5 Global Hepatic Encephalopathy (HE) Therapeutics Market Size
        • 1.5.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue (2014-2025)
        • 1.5.2 Global Hepatic Encephalopathy (HE) Therapeutics Production (2014-2025)

      2 Global Hepatic Encephalopathy (HE) Therapeutics Market Competition by Manufacturers

      • 2.1 Global Hepatic Encephalopathy (HE) Therapeutics Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Hepatic Encephalopathy (HE) Therapeutics Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Hepatic Encephalopathy (HE) Therapeutics Production Sites, Area Served, Product Types
      • 2.5 Hepatic Encephalopathy (HE) Therapeutics Market Competitive Situation and Trends
        • 2.5.1 Hepatic Encephalopathy (HE) Therapeutics Market Concentration Rate
        • 2.5.2 Hepatic Encephalopathy (HE) Therapeutics Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Hepatic Encephalopathy (HE) Therapeutics Production Market Share by Regions

      • 3.1 Global Hepatic Encephalopathy (HE) Therapeutics Production Market Share by Regions
      • 3.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Hepatic Encephalopathy (HE) Therapeutics Production
        • 3.4.1 North America Hepatic Encephalopathy (HE) Therapeutics Production Growth Rate (2014-2019)
        • 3.4.2 North America Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Hepatic Encephalopathy (HE) Therapeutics Production
        • 3.5.1 Europe Hepatic Encephalopathy (HE) Therapeutics Production Growth Rate (2014-2019)
        • 3.5.2 Europe Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Hepatic Encephalopathy (HE) Therapeutics Production (2014-2019)
        • 3.6.1 China Hepatic Encephalopathy (HE) Therapeutics Production Growth Rate (2014-2019)
        • 3.6.2 China Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Hepatic Encephalopathy (HE) Therapeutics Production (2014-2019)
        • 3.7.1 Japan Hepatic Encephalopathy (HE) Therapeutics Production Growth Rate (2014-2019)
        • 3.7.2 Japan Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Hepatic Encephalopathy (HE) Therapeutics Consumption by Regions

      • 4.1 Global Hepatic Encephalopathy (HE) Therapeutics Consumption by Regions
      • 4.2 North America Hepatic Encephalopathy (HE) Therapeutics Consumption (2014-2019)
      • 4.3 Europe Hepatic Encephalopathy (HE) Therapeutics Consumption (2014-2019)
      • 4.4 China Hepatic Encephalopathy (HE) Therapeutics Consumption (2014-2019)
      • 4.5 Japan Hepatic Encephalopathy (HE) Therapeutics Consumption (2014-2019)

      5 Global Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price Trend by Type

      • 5.1 Global Hepatic Encephalopathy (HE) Therapeutics Production Market Share by Type (2014-2019)
      • 5.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2014-2019)
      • 5.3 Global Hepatic Encephalopathy (HE) Therapeutics Price by Type (2014-2019)
      • 5.4 Global Hepatic Encephalopathy (HE) Therapeutics Production Growth by Type (2014-2019)

      6 Global Hepatic Encephalopathy (HE) Therapeutics Market Analysis by Applications

      • 6.1 Global Hepatic Encephalopathy (HE) Therapeutics Consumption Market Share by Application (2014-2019)
      • 6.2 Global Hepatic Encephalopathy (HE) Therapeutics Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Hepatic Encephalopathy (HE) Therapeutics Business

      • 7.1 ASKA Pharmaceutical
        • 7.1.1 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Production Sites and Area Served
        • 7.1.2 Hepatic Encephalopathy (HE) Therapeutics Product Introduction, Application and Specification
        • 7.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 COSMO PHARMACEUTICALS
        • 7.2.1 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Production Sites and Area Served
        • 7.2.2 Hepatic Encephalopathy (HE) Therapeutics Product Introduction, Application and Specification
        • 7.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Mallinckrodt
        • 7.3.1 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Production Sites and Area Served
        • 7.3.2 Hepatic Encephalopathy (HE) Therapeutics Product Introduction, Application and Specification
        • 7.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Valeant
        • 7.4.1 Valeant Hepatic Encephalopathy (HE) Therapeutics Production Sites and Area Served
        • 7.4.2 Hepatic Encephalopathy (HE) Therapeutics Product Introduction, Application and Specification
        • 7.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served

      8 Hepatic Encephalopathy (HE) Therapeutics Manufacturing Cost Analysis

      • 8.1 Hepatic Encephalopathy (HE) Therapeutics Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Hepatic Encephalopathy (HE) Therapeutics
      • 8.4 Hepatic Encephalopathy (HE) Therapeutics Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Hepatic Encephalopathy (HE) Therapeutics Distributors List
      • 9.3 Hepatic Encephalopathy (HE) Therapeutics Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Hepatic Encephalopathy (HE) Therapeutics Market Forecast

      • 11.1 Global Hepatic Encephalopathy (HE) Therapeutics Production, Revenue Forecast
        • 11.1.1 Global Hepatic Encephalopathy (HE) Therapeutics Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Hepatic Encephalopathy (HE) Therapeutics Price and Trend Forecast (2019-2025)
      • 11.2 Global Hepatic Encephalopathy (HE) Therapeutics Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Hepatic Encephalopathy (HE) Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Hepatic Encephalopathy (HE) Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Hepatic Encephalopathy (HE) Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Hepatic Encephalopathy (HE) Therapeutics Production, Revenue Forecast (2019-2025)
      • 11.3 Global Hepatic Encephalopathy (HE) Therapeutics Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Hepatic Encephalopathy (HE) Therapeutics Consumption Forecast (2019-2025)
        • 11.3.2 Europe Hepatic Encephalopathy (HE) Therapeutics Consumption Forecast (2019-2025)
        • 11.3.3 China Hepatic Encephalopathy (HE) Therapeutics Consumption Forecast (2019-2025)
        • 11.3.4 Japan Hepatic Encephalopathy (HE) Therapeutics Consumption Forecast (2019-2025)
      • 11.4 Global Hepatic Encephalopathy (HE) Therapeutics Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Hepatic Encephalopathy (HE) Therapeutics Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
        The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.
        The most commonly used therapeutics to treat HE are lactulose and rifaximin. Researchers are also developing treatments that targets ammonia production and removal. For instance, AST-120 is under investigation and targets gut-derived toxins for liver cirrhosis. It can also be used to treat HE. The progression and development of HE sometimes depends on factors such as inflammation. This is compelling researchers to introduce various treatments that targets inflammation. Some of the most recent approaches to treat HE includes probiotics, albumin administration, and dialysis. Such emergence of novel hepatic encephalopathy treatment targets is identified as one of the key trends that will stimulate growth in the hepatic encephalopathy (HE) therapeutics market during the forecasted period.

        The global Hepatic Encephalopathy (HE) Therapeutics market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Hepatic Encephalopathy (HE) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hepatic Encephalopathy (HE) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        ASKA Pharmaceutical
        COSMO PHARMACEUTICALS
        Mallinckrodt
        Valeant
        ...

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        Lactulose
        Rifaximin
        Neomycin
        Probiotics
        Thiamine

        Segment by Application
        Acute Liver Failure
        Portal Systemic Bypass Without Liver Disease
        Liver Cirrhosis

        Buy now